The clinical importance of KIT mutations in melanoma and the role of activated KIT in disease spread and progression relates to the fact that drugs for inhibition of its kinase activity such as imatinib, dasatinib and nilotinib are readily available and are already used successfully in patients with advanced metastatic melanoma and other cancers [17–20]. This evidence concerns the gene KIT and metastatic melanoma.